<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408447</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA7701</org_study_id>
    <secondary_id>CHNY-01-503</secondary_id>
    <nct_id>NCT00408447</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant in Sickle Cell Disease and Thalassemia</brief_title>
  <official_title>Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately&#xD;
      ablative) will result in successful bone marrow replacement without as severe side-effects&#xD;
      but with permanent control of the disease. Patients will receive a chemotherapy regimen with&#xD;
      busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a&#xD;
      family-related or cord-blood matched donor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease is a genetic disorder in which a mutation in the beta chain of human&#xD;
      hemoglobin results in abnormal blood hemoglobin, causing red blood cells to sickle under&#xD;
      stress with resulting symptoms including severe pains and strokes. Beta thalassemia is&#xD;
      another genetic disorder in which there are abnormal beta hemoglobin chains, causing anemia.&#xD;
      In both disorders, frequent red blood cell transfusions may be required to sustain life, but&#xD;
      these often result in complications including multiple hospitalizations, iron overload, or&#xD;
      bacterial or viral infections such as hepatitis. Standard drugs and therapies used in the&#xD;
      treatment of sickle cell disease and/or beta thalassemia provide only supportive care, and&#xD;
      may result in long-term side effects, and inadequate control of the disease process. Bone&#xD;
      marrow transplant has been increasingly used for the long-term treatment and cure of sickle&#xD;
      cell disease and beta thalassemia. Although, not without acute and potential long term side&#xD;
      effects, this alternative offers long term control and potential cure of the disease. Most of&#xD;
      the side effects seen with bone marrow transplant are directly related to the high intensity&#xD;
      of chemotherapy used (ablative).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2004</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of toxicity associated with moderately ablative therapy (busulfan/fludarabine/alemtuzumab) and allogeneic stem cell transplantation in selected patients with Sickle Cell Disease (SCD) and Beta Thalassemia (BT)</measure>
    <time_frame>Day 30, Day 60, Day 100, Day 180, 1 year, 2 years, 3 years, 5 years, 10 years</time_frame>
    <description>To examine if giving lower doses of chemotherapy will result in less severe side-effects but with permanent control of the disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to donor hematological reconstitution (neutrophil, red blood cell and platelet recovery) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT</measure>
    <time_frame>days 60, 100, 180, 365, 730</time_frame>
    <description>To examine if giving lower doses of chemotherapy and bone marrow replacement can result in control of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft versus host disease (GVHD) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT</measure>
    <time_frame>as clinically appropriate</time_frame>
    <description>To examine if giving lower doses of chemotherapy will result in successful bone marrow replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who have either a complete, very good partial, partial or no response (clinical/laboratory) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT</measure>
    <time_frame>6mos, 1 yr, 2 yr</time_frame>
    <description>To examine if giving lower doses of chemotherapy with bone marrow replacement will result in good control of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) score</measure>
    <time_frame>Day +180; year 1, 3, 5, 10</time_frame>
    <description>To determine the impact of moderately ablative stem cell transplant on quality of life and neurocognitive functioning with SCD over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure</measure>
    <time_frame>Day +42, +60,</time_frame>
    <description>To collect data on graft failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of mixed donor chimerism</measure>
    <time_frame>Day +30, 60, 100, 180, 365, 730, and 1005</time_frame>
    <description>To collect data on donor chimerism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Beta Thalassemia</condition>
  <arm_group>
    <arm_group_label>SCD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan 4 mg/kg/d x 4d</description>
    <arm_group_label>BT group</arm_group_label>
    <arm_group_label>SCD group</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2/d x 6d</description>
    <arm_group_label>BT group</arm_group_label>
    <arm_group_label>SCD group</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d</description>
    <arm_group_label>BT group</arm_group_label>
    <arm_group_label>SCD group</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic stem cell transplant</intervention_name>
    <description>Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.</description>
    <arm_group_label>BT group</arm_group_label>
    <arm_group_label>SCD group</arm_group_label>
    <other_name>Related Bone Marrow</other_name>
    <other_name>Related Cord Blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Sickle Cell Disease:&#xD;
&#xD;
          -  Diagnosis of Homozygous Hemoglobin S Disease or Heterozygous Hemoglobin Sickle Cell&#xD;
             (SC) or S 0/+ thalassemia, or Sickle/variant resulting in Chronic Hemolytic Anemia&#xD;
             with hemoglobin (HgB) ≤10 mg/dL&#xD;
&#xD;
          -  Age ≤30&#xD;
&#xD;
          -  Matched sibling donor and asymptomatic, or 8/8 human leukocyte antigen (HLA) matched&#xD;
             unrelated adult donor&#xD;
&#xD;
        Patient must have adequate organ function as below:&#xD;
&#xD;
          -  Adequate renal function defined as serum creatinine ≤1.5 x normal, or Creatinine&#xD;
             clearance or radioisotope glomerular filtration rate (GFR) &gt;100 ml/min/1.73 m2 or&#xD;
             &gt;70ml/min/1.73m2 for patients &gt;16 years old&#xD;
&#xD;
          -  Adequate liver function defined as serum glutamic oxaloacetic transaminase (SGOT)&#xD;
             (aspartate aminotransferase (AST)) or serum glutamic-pyruvic transaminase (SGPT)&#xD;
             (alanine aminotransferase (ALT)) &lt; 5.0 x normal&#xD;
&#xD;
          -  Adequate Cardiac Function defined as shortening fraction of ≥28% by echocardiogram, or&#xD;
             ejection fraction of ≥48% by radionuclide angiogram or echocardiogram&#xD;
&#xD;
          -  Adequate pulmonary function defined as corrected Diffusing capacity of the lungs for&#xD;
             carbon monoxide (DLCO) ≥40% by pulmonary function test, or for children who are unable&#xD;
             to perform DLCO maneuver ≥85% O2 saturation, no evidence of dyspnea at rest&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Karnofsky/Lansky Performance Score &lt;60%&#xD;
&#xD;
          -  Demonstrated lack of compliance with medical care&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Evidence of uncontrolled bacterial, viral or fungal infections (currently taking&#xD;
             medication and progression of clinical symptoms) within 1 month prior to starting the&#xD;
             conditioning regimen. Patients with fever or suspected minor infection should await&#xD;
             resolution of symptoms before starting the conditioning regimen.&#xD;
&#xD;
        Histologic Exam of Liver (liver biopsy) with bridging fibrosis or cirrhosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant. 2005 Jun;11(6):403-22. Review.</citation>
    <PMID>15931629</PMID>
  </reference>
  <reference>
    <citation>Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D, Yamashiro DJ, Garvin J, Skerrett D, Bessmertny O, Wolownik K, Wischhover C, van de Ven C, Cairo MS. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant. 2004 Mar;33(6):613-22.</citation>
    <PMID>14730337</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2006</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell transplant</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>thalassemia</keyword>
  <keyword>moderately ablative</keyword>
  <keyword>cord blood transplant</keyword>
  <keyword>matched family donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

